Tumour markers in malignancies

British Medical Journal

Volumn 320, Issue 7232, 2000, Pages 424-427

  Lindblom, Annika ^a   Liljegren, Annelie ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CATECHOLAMINE; ESTROGEN RECEPTOR; MONOPHENOL MONOOXYGENASE; PROSTATE SPECIFIC ANTIGEN; STEROID; THYROGLOBULIN; TUMOR MARKER;

BLOOD ANALYSIS; BLOOD CELL; BONE MARROW CELL; BREAST CANCER; CANCER; CHROMOSOME TRANSLOCATION; COLORECTAL CANCER; FECES ANALYSIS; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LIPOSARCOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MELANOMA; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SARCOMA; SHORT SURVEY; TESTIS CANCER; THYROID CANCER; TUMOR CELL; URINALYSIS; CHEMISTRY; METHODOLOGY; NEOPLASM; REVIEW;

HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0034639783     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (35)

1. 1 Melo JV. The molecular biology of chronic myeloid leukemia. Leukemia 1996;10:751-6.
2. 2 Heim S, Milelmann F. Cancer cytogenetics. Chromosomal and molecular genetic aberrations of tumor cells. 2nd ed. New York: Wiley, 1994 .
3. 3 Hunerbein M. The value of tumor markers in colorectal cancer. Recent Results Cancer Res 1998;146:48-55.
4. 4 Lamerz R. AFP isoforms and their clinical significance. Anticancer Res 1997;17:2927-30.
5. 5 Kuban DA, El-Mahdi A, Schellhammer PF. PSA For outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? Semin Oncol 1998;8:72-80.
6. 6 Shivers SC, Wang X, Li W, Joseph EM, Glass LF, DeConti R, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. N Engl J Med 1998;280:1410-5.
7. 7 Pelkey TJ, Frierson HF, Bruns DE. Molecular and imnumological detection of circulating tumor cells and micrometastases from solid tumors, Clin Chem 1996;42:1369-81.
8. 8 Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technologv in the detection of solid tumors. Cancer 1998;82:1419-42.
9. 9 Blennerhasseu GT, Furth ME, Anderson A, Burn JP, Changanti RS, Blick M, et al. Clinical evaluation of a DNA probe assay for the Philadelphia (Phl) translocation in chronic myelogenous leukemia. Leukemia 1988;2:648-57.
10. 10 Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer. Literature review for clinical application. Div Colon Rectum 1998;41:1033-49.
11. 11 Liefers G-J, Cleton-Jansen A-M, van de Velde CJH, Hermans J, van Krieken JHJM, Cornelisse CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223-8.
12. 12 American Society of Clinical Oncology. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1998;16:793-5.
13. 13 Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
14. 14 Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65-77.
15. 15 Montie JE, Meyers SE. Defining the ideal tumor marker for prostate cancer. Urol Clin North Am 1997;24:247-52.
16. 16 McCarthy M. PSA screening said to reduce prostate cancer deaths, or does it? Lancet 1998;351:1563.
17. 17 Olsson CA, Devries GM, Raffo AJ, Benson MC, Otoole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate-specific antigen predicts treatment failure following radical prostatectomy.J Urol 1996;155:1557-62.
18. 18 Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-9.
19. 19 Ladenson PW. Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Clin Chem 1996;42:183-7.
20. 20 Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338:153-60.
21. 21 Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, et al. The EWS-WTI translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet 1997;17:309-13.
22. 22 Arden KC, Anderson MJ, Finckenstein FG, Czekay S, Cavenee WK. Detection of the t(2:13) chromosomal translocation in alveolar rhabdomyosarcomah using the reverse transcriptase polymerase chain reaction. Genes Chrom Cancer 1996;16:254-60.
23. 23 Bown NP, Rowe D, Reid MM. Granulocytic sarcoma with translocation (9;11)(p22;q23): two cases. Cancer Genet Cytogenet 1997;96:115-7.
24. 24 Dei Tos AP, Dal Cin P. The role of cytogenetics in the classification of soft tissue tumours. Virchows Arch 1997;431:83-94.
25. 25 Hisaoka M, Tsuji S, Morimitsu Y, Hashimoto H, Shimajairi S, Koiya S, et al. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription polymerase chain reaction using archival paraffin-embedded tissues. Diagnostic Mol Pathol 1998;7:96-101.
26. 26 Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998;18:184-7.
27. 27 Speleman F, Delaltre O, Peter M, Hauben E, Van Roy N, Van Marck E. Malignant melanoma of the soft parts (clear-cell sarcoma): confirmation of EWS and ATF-1 gene fusion caused by a t(12:22) translocation. Mod Pathol 1997;10:496-9.
28. 28 Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre JM, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COLIAI in dermatofibrosarcoma protuberans and giant cell fibroblastoma. Nature Genet 1997;15:95-8.
29. 29 Dean RC, Moul JW. New tumor markers of testis cancer. Urol Clin North Am 1998;25:365-73.
30. 30 Forestier E, Gustafsson G, von Hedeman A, Heim S,Hernell O, Mitelman F, et al. Prognostic impact of bone marrow karyotype in childhood acute lymphoblastic leukaemia: Swedish experiences 1986-91. Acta Paediatr 1997;86:819-25.
31. 31 Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 1990;76:489-94.
32. 32 Heerema NA, Arthur DA, Sather H, Albo V, Feusner J, Lange BJ, et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Children Cancer Group. Blood 1990;83:2274-84.
33. 33 Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996;132:42-7.
34. 34 Ristamaki R, Joensuu H, Lappalainen K, Teerenhovi L, Jalkanen S. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. Blood 1997;90:4039-45.
35. 35 Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer. N Engl J Med 1998;339:941-6.